This biotech company develops bioprinted tissue therapeutics to create functional human tissues for transplantation and regenerative medicine. By addressing the shortage of donor organs and the limitations of traditional tissue engineering, their technology aims to improve patient outcomes in disease treatment.

Deep Genomics utilizes a proprietary AI platform to analyze complex RNA biology data, identifying novel therapeutic targets for genetic conditions. By streamlining the drug discovery process, the company aims to develop RNA therapies that can precisely target genetic causes, significantly reducing the time and cost associated with traditional methods.

Didadem Biotherapeutics is developing engineered exosomes through its DECOSTAR™ platform to activate immune receptors for the treatment of autoimmune conditions and cancers. This technology addresses the need for effective immunotherapy by enhancing agonist signaling to target validated therapeutic pathways.

The startup operates a healthcare delivery organization that provides integrated, community-based care specifically designed for frail elderly individuals. By utilizing a scalable program of all-inclusive care, the company streamlines medical and social services, enabling seniors to age in their preferred locations while maintaining meaningful connections and quality of life.

Epitopea develops off-the-shelf RNA immunotherapies that target aberrantly expressed tumor-specific antigens (aeTSAs) identified through its proprietary CryptoMap™ platform. This approach aims to enhance cancer treatment efficacy by providing durable benefits while minimizing side effects for patients with difficult-to-treat cancers.

ExCellThera specializes in hematopoietic stem cell (HSC) expansion and rejuvenation through its proprietary Enhance™ platform, enabling the development of allogeneic stem cell therapies for blood cancers. The company addresses the need for effective treatments in hematological malignancies by enhancing the quantity and quality of stem cells used in therapeutic applications.

GenXys provides precision prescribing software that integrates pharmacogenetic data to tailor medication choices based on individual patient profiles. This platform enhances clinical decision-making by streamlining medication selection and authorization processes, ultimately improving patient safety and treatment outcomes.

Mesentech has developed a tissue-selective drug delivery system that utilizes novel chemistry to target pharmaceuticals specifically to musculoskeletal tissue, minimizing exposure to non-target organs. Their first clinical program focuses on delivering prostaglandin to enhance the body's regenerative processes for muscle and bone repair.

MetaOptima provides a skin analytics platform, DermEngine, that utilizes artificial intelligence to enhance dermatological workflows and patient communication, alongside MoleScope, a digital dermoscopic attachment for smartphones that captures medical-grade skin images. These tools enable medical professionals to deliver faster and more accurate skin care, addressing the need for improved diagnostic capabilities in dermatology.

mimik provides a hybrid edge cloud platform that enables smart devices to function as both clients and cloud servers, facilitating real-time data processing and collaboration at the edge. This approach minimizes bandwidth usage and latency while enhancing security and data privacy, addressing the inefficiencies of traditional cloud computing models.

The startup has developed a nasal clip that applies constant, hands-free pressure to the nasal side walls while delivering vasoconstrictive medication through pre-medicated sponges to control nosebleeds in both children and adults. This device enhances patient care by providing adjustable sizing and an optional facial cooling pack to constrict blood vessels and reduce inflammation.

Optigo Biotherapeutics develops novel biotherapeutics to treat chronic ophthalmic diseases and prevent vision loss. They are focused on creating innovative treatments for debilitating eye conditions.

Rakovina Therapeutics Inc utilizes the Deep Docking AI Platform to accelerate drug discovery for oncology, focusing on biomarker-driven treatments for various tumor types. The company is developing a pipeline of potential therapies, including kt-2000 AI and the kt-3000 series, aimed at addressing the need for effective cancer treatments that target DNA damage response mechanisms.

SafKan Health has developed the OtoSet® Ear Cleaning System, an automated device that utilizes irrigation and micro-suction technology to effectively remove earwax buildup in a quick and mess-free manner. This solution addresses the common issue of earwax impaction, which can lead to discomfort and hearing difficulties for millions of Americans.

Sonic Incytes develops the VELACUR device, an AI-guided 3D S-WAVE ultrasound elastography system that measures liver stiffness and attenuation to assess fatty liver disease at the point of care. This technology provides real-time, non-invasive diagnostics with deeper measurements and larger tissue samples, enabling trained medical professionals to deliver accurate results without requiring extensive sonography experience.

The startup develops synthetic live biotherapeutic drugs that utilize engineered probiotics to provide targeted therapeutic activities against diseases resistant to conventional treatments. By addressing bacterial resistance and enhancing treatment efficacy, the company enables healthcare providers to offer effective solutions for conditions that traditional pharmaceuticals cannot manage.

The startup develops antineoplastic therapeutics using proprietary scaffold redesign and hopping technology, which integrates mechanism of action and chemical design to target previously undruggable cancer pathways. This approach enables drug researchers to screen trillions of molecules for resistance prediction and antibody redesign, enhancing the durability of therapeutic responses.

The startup develops a specialized cannula designed for minimally invasive cardiopulmonary bypass surgery, aimed at preventing patient injury during extracorporeal circulation. This device enhances safety by minimizing the risk of complications associated with traditional surgical methods.

Virogin Biotech develops oncolytic HSV-1 viruses and mRNA-based therapeutics to generate robust anti-tumor immune responses against solid tumors. Their dual-platform approach enhances the efficacy of cancer immunotherapy, with candidates currently in clinical trials and preclinical stages.

IMBiologics develops immunomodulatory antibody therapeutics utilizing bispecific antibody technology to restore immune system balance in patients with autoimmune diseases and cancer. Their platform accelerates the creation of novel treatment options, addressing the need for effective therapies in these challenging medical areas.

The startup develops a subcutaneous injection drug therapy that prevents hypoglycemia in individuals with diabetes. This therapy aims to reduce the morbidity and mortality associated with hypoglycemic events, thereby enhancing diabetes management and improving patient health outcomes.